Express Pharma

Venus Remedies bags first Mexican patent for research product

0 91

Venus Remedies has received its first patent from Mexico for ‘Vancoplus’, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. The patent has been granted from the Mexico Patent office and is valid till February 2026.

Speaking on this achievement, Dr Manu Chaudhary, Joint Managing Director and Director-Research, Venus Remedies says, “Receiving a patent grant from Mexico for our research product Vancoplus at this point in time when the frequency of MRSA strains is growing high (50-85 per cent) in Mexico is a great achievement for us. Vancoplus will prove to be the best known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria in a situation wherein around 3 to 6 per cent of the population carries the community form of MRSA.”

As per the CDC reports published in the Journal of the American Medi